EMA Authorised: Skyrizi (risankizumab) — AbbVie Deutschland GmbH & Co. KG

View source ↗

Summary

EU authorisation of Skyrizi (risankizumab) for multiple inflammatory diseases including psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Psoriasis
• Psoriatic Arthritis
• Ulcerative Colitis

Drugs mentioned

• SKYRIZI (risankizumab-rzaa)

Snippet

Status: Authorised. Therapeutic area: Psoriasis;Arthritis, Psoriatic;Colitis, Ulcerative;Crohn Disease. MAH: AbbVie Deutschland GmbH & Co. KG. Decision date: 19/06/2026